Bsense Bio Therapeutics

Company Overview

Snapshot

Founded in September 2018 by Prof. Bernard Attali, Bsense Bio Therapeutics operates with 1–10 employees. The company has raised $2.7 million across one funding round from 5 investors, including Johnson & Johnson Innovation. In September 2018, the company secured seed funding from Johnson & Johnson Innovation and OrbiMed.

Business overview

Bsense Bio Therapeutics is a Health Tech & Life Sciences company focused on developing small molecules for neuropathic pain treatment. The company employs a novel approach targeting multiple pain-related mechanisms with a single compound, specifically focusing on cation channels (TRPV1 and Kv7.2/3) co-localized on sensory nociceptive neurons. Operating within the Pharmaceuticals sector, Bsense Bio Therapeutics is currently assessing the in vitro specificity and selectivity of lead compounds to progress into in vivo safety and efficacy studies, while also performing structural activity relation studies to improve compound characteristics.

Company Intelligence Q&A

What is Bsense Bio Therapeutics' primary focus?

Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain, pioneering a novel approach that targets multiple pain-related mechanisms using a single compound for enhanced efficacy and safety.

Which specific biological targets does Bsense Bio Therapeutics' approach address?

Bsense Bio Therapeutics' approach targets two cation channels, TRPV1 and Kv7.2/3, which are co-localized on sensory nociceptive neurons and are recognized as key players in pain signaling.

What is the current stage of Bsense Bio Therapeutics' product development?

Bsense Bio Therapeutics is currently assessing the in vitro specificity and selectivity of three lead compounds and performing structural activity relation studies to develop backup compound series, with the goal of progressing into in vivo safety and efficacy studies.

Which investors participated in Bsense Bio Therapeutics' seed funding round?

In September 2018, Bsense Bio Therapeutics secured seed funding from Johnson & Johnson Innovation and OrbiMed.

What is the total capital raised by Bsense Bio Therapeutics?

Bsense Bio Therapeutics has raised a total of $2.7 million across one funding round.